Table 1
| Evaluable patients* | Melanoma | RCC | TCC | NSCLC | EA | SCCHN |
|---|---|---|---|---|---|---|
| n(%) | (n=7) | (n=5) | (n=2) | (n=2) | (n=2) | (n=1) |
| ORR (CR+PR) | 4 (57) | 2 (40) | 1 (50) | 1 (50) | 1 (50) | 1 (100) |
| CR | 2 (29) | 0 | 0 | 0 | 0 | 0 |
| PR | 2 (29) | 2 (40) | 1 (50) | 1 (50) | 1 (50) | 1 (100) |
| SD | 2 (29) | 2 (40) | 0 | 1 (50) | 0 | 0 |
| DCR (CR+PR+SD) | 6 (86) | 4 (80) | 1 (50) | 2 (100) | 1 (50) | 1 (100) |
| PD | 1 (14) | 0 | 1 (50) | 0 | 0 | 0 |
| Not assessable | 0 | 1 (20) | 0 | 0 | 1 (50) | 0 |
*Patients with ≥ 1 post-baseline response assessment or discontinued from study or died before response could be assessed.